OOIR: Observatory of International Research

Papers

(The TQCC of Seminars in Hematology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Iron biology: the balance matters	59
outside front cover, PMS 8883 metallic AND 4/C	52
Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment of LBCL in 2023	49
Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?	43
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients	42
Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach	39
Forging international collaboration and alliances to establish the largest transplant center in the north of Vietnam	36
CAR T-cell therapy comes of age: Introductory editorial for the special issue	34
Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia	33
Epidemiology of VITT	33
Clinical applications of circulating tumor DNA in Hodgkin lymphoma	33
Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapy	27
Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana	26
Patient-reported outcomes in early phase trials for patients with myelodysplastic syndromes	25
Therapy-related myelodysplastic syndromes and acute myeloid leukemia	24
Laboratory testing for VITT antibodies	23
Clonal hematopoiesis in the setting of hematopoietic cell transplantation	21
Cell senescence and malignant transformation in the inherited bone marrow failure syndromes: Overlapping pathophysiology with therapeutic implications	20
Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation	14
Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial	14
Looking to achieve cure the first time around for DLBCL patients who are older and/or with co-morbidities	14
outside front cover, PMS 8883 metallic AND 4/C	13
Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin	13
License for a CAR T: Examining patient eligibility	12
Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa	12

Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients	11
The role of response adapted therapy in the era of novel agents	11
The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors	10
Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies	9
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria	9
Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress	9
Palliative care needs of patients with hematologic malignancies and family caregivers and challenges of palliative care provision in Asia: A review of evidence	9
outside front cover, PMS 8883 metallic AND 4/C	8
The psychiatric and psychological sequelae of vaccine-induced immune thrombotic thrombocytopenia (VITT)	8
Advances in understanding the crosstalk between mother and fetus on iron utilization	8
Germline predisposition for clonal hematopoiesis	8
Shaping the bone through iron and iron-related proteins	7
Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care	7
The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era	7
Platelet-activating anti-PF4 disorders: An overview	7
How to set up a clinical research center in Brazil, as an example of a middle-income country	6
Metabolic reprogramming in the CLL TME; potential for new therapeutic targets	6
Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management	6
Updates on the biology of chronic lymphocytic leukemia: introductory editorial	6
outside front cover, PMS 8883 metallic AND 4/C	6
Collaborations, colleagues, and friendships: The Hematology Branch and blood disease centers in Asia	6
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19	5
CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?	5
Smoldering multiple myeloma: Integrating biology and risk into management	5
Management of Angioimmunoblastic T-Cell Lymphoma (AITL) and other T Follicular Helper Cell lymphomas (TFH PTCL)	5
Inflammation in myelodysplastic syndrome pathogenesis	5
Somatic mutations and clonal expansions in paroxysmal nocturnal hemoglobinuria	5
RNA splicing as a therapeutic target in myelodysplastic syndromes	5
Cell-free DNA in large B-cell lymphoma: MRD and beyond	5
Mouse models of CLL: In vivo modeling of disease initiation, progression, and transformation	5